Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes

NCT05819138 on ClinicalTrials.gov · last registry update 2026-03-04

A small phase 3 — 60 participants, against a typical 424. Due to report 1 October 2027, alongside 39 other tracked readouts that quarter. Primary outcome, as filed: Change in Ascending Aortic Pulse Wave Velocity (AA PWV). Sponsors move these dates routinely; any movement since this site started watching is listed below. It has been running since 21 June 2023 — 3 years so far. semaglutide is approved in the US, but not for type 1 diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: RECRUITING
Phase: P3
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: University of Colorado, Denver
Sponsor type: Other
Enrollment: 60
Started: 2023-06-21
Primary completion: 2027-10-01 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in Ascending Aortic Pulse Wave Velocity (AA PWV)

Conditions studied

Diabetes Mellitus, Type 1

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.